Most notably, germline modifications that reduce basal levels of Myc expression, such as enhancer deletion or Myc+/– haploinsufficiency, afford significant protection from a wide variety of adult-onset cancers while having surprisingly little evident impact on normal mouse development and adult tissue homeostasis13,21,23,24,27,28,31. This evidence concerns the gene MYC and cancer.